White Paper — Sponsored Content

Paving the Road to Allogeneic CAR-T Therapy Manufacturing

Paving the Road to Allogeneic Car-T Therapy Manufacturing

The demand for cell and ex-vivo gene therapies is steadily increasing, given the impressive efficacy of autologous chimeric antigen receptor T-cell (CAR-T) therapies against hematological malignancies. In recent years, the reality of curative treatment and commercial approval of several autologous CAR-T products triggered developers to plan for increased capacity and treating larger patient populations. Pioneers in the CAR-T therapy space are also heavily investing in allogeneic platforms to create off-theshelf therapeutic cells that are immediately available and can treat a large number of patients with a single product batch.

Download White Paper

To download this white paper, complete the form below. Once submitted, you will receive a link via the email you provided to download the white paper.

Company Type

By completing this form, you consent to have your information provided to the third-party sponsor of this content and may use your information to provide information about relevant products, services, and other opportunities which may be of interest to you . ISPE will store your information in a secure environment and may use your information to provide information about relevant products, services, and other opportunities which may be of interest to you. You may unsubscribe from these ISPE communications at any time. For more information or to unsubscribe, review our Privacy Policy or contact us at ask@ispe.org.

Product Development
Biotech